Clinical trial
Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis…
NCT00347048 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00347048 |
|---|---|
| Title | Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients |
| Official title | Tacrolimus (FK506) P-III Placebo-Controlled Double-Blind Study in Moderate to Severe Refractory Ulcerative Colitis Patients |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | tacrolimus, Placebo |
| Enrollment | 62 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Jul 4, 2006 |
| Last update posted | Aug 26, 2014 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: